Literature DB >> 8556529

Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.

W Cleare1, S Mukherjee, E D Spitzer, A Casadevall.   

Abstract

Monoclonal antibody (MAb) 2H1 binds to an epitope in the capsule of Cryptococcus neoformans that can elicit protective antibodies. The binding of MAb 2H1 to C. neoformans strains was studied by agglutination, immunofluorescence, and phagocytosis assays. The MAb 2H1 epitope was present in all 21 isolates studied, including those recovered from patients with recurrent infections.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8556529      PMCID： PMC368405          DOI： 10.1128/cdli.1.6.737-740.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  28 in total

1.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

2.  Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture.

Authors:  S M Levitz; T P Farrell; R T Maziarz
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

3.  Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action.

Authors:  F Dromer; J Charreire
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

4.  Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.

Authors:  S J Devi; R Schneerson; W Egan; T J Ulrich; D Bryla; J B Robbins; J E Bennett
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  Persistence of initial infection in recurrent Cryptococcus neoformans meningitis.

Authors:  E D Spitzer; S G Spitzer; L F Freundlich; A Casadevall
Journal:  Lancet       Date:  1993-03-06       Impact factor: 79.321

6.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

7.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

8.  Use of a dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neoformans.

Authors:  E D Spitzer; S G Spitzer
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

9.  Extensive allelic variation in Cryptococcus neoformans.

Authors:  A Casadevall; L F Freundlich; L Marsh; M D Scharff
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

10.  Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.

Authors:  J Chan; Y Xing; R S Magliozzo; B R Bloom
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307
View more
  7 in total

1.  In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.

Authors:  W Cleare; R Cherniak; A Casadevall
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

2.  Biological activity of a mouse-human chimeric immunoglobulin G2 antibody to Cryptococcus neoformans polysaccharide.

Authors:  Katherine Westin Kwon; Nikoletta Lendvai; Sherie Morrison; K Ryan Trinh; Arturo Casadevall
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

3.  The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.

Authors:  W Cleare; A Casadevall
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

4.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 6.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

7.  Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.

Authors:  J Mukherjee; M Feldmesser; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.